3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Head & Neck
11
Sarcoma
4
Gynecologic
4
Genitourinary
3
Gastrointestinal
3
Breast
3
Thoracic
2
Dermatologic
2
NET
1
Lymphoid
1
Endocrine
1
CNS
1
Conditions
Melanoma
147
Carcinoma, Non-Small-Cell Lung
34
Skin Neoplasms
28
Colorectal Neoplasms
28
Breast Neoplasms
25
Lung Neoplasms
24
Carcinoma, Renal Cell
21
Ovarian Neoplasms
20
Neoplasms
20
Squamous Cell Carcinoma of Head and Neck
19
Carcinoma, Basal Cell
19
Carcinoma, Merkel Cell
18
Sarcoma
17
Prostatic Neoplasms
17
Pancreatic Neoplasms
16
Neoplasm Metastasis
15
Head and Neck Neoplasms
14
Stomach Neoplasms
13
Thyroid Neoplasms
12
Uterine Cervical Neoplasms
11
Urinary Bladder Neoplasms
11
Carcinoma, Hepatocellular
11
Lymphoma, T-Cell, Cutaneous
10
Esophageal Neoplasms
10
Carcinoma, Transitional Cell
9
Uveal Melanoma
8
Triple Negative Breast Neoplasms
8
Mycosis Fungoides
8
Colonic Neoplasms
8
Small Cell Lung Carcinoma
7
Interventions
trastuzumab deruxtecan
1
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Dermatologic
×
30 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA